Active Biotech (ACTI) Q1 2026 earnings summary

Executive summary

• Focused on advancing tasquinimod in myelofibrosis and business development for laquinimod in inflammatory eye disorders.

• Achieved key milestones: US patent granted for tasquinimod, positive FDA feedback, and resumed patient enrollment in US myelofibrosis study.

• Published preclinical data for tasquinimod in myelodysplastic neoplasms and LION study results for laquinimod.

Financial highlights

• No net sales recorded in Q1 2026.

• Operating loss was SEK 8.6M, a 23% improvement from SEK 11.2M in Q1 2025.

• Research and development expenses decreased 29% year-over-year to SEK 5.8M.

• Loss after tax was SEK 8.4M, compared to SEK 11.0M in Q1 2025.

• Cash and cash equivalents at period end were SEK 53.3M, down from SEK 65.1M at year-end 2025.

Outlook and guidance

• Ongoing proof-of-concept studies for tasquinimod in myelofibrosis in the US and Europe, with interim readouts expected late 2026 and efficacy results by end of 2027.

• Laquinimod is phase II ready; partnering activities are ongoing to secure a commercial partner.

• Available liquidity expected to fund operations through 2026 and 2027.